On May 16, 2025, Plus Therapeutics, Inc. received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share due to its stock price falling below this level for 30 consecutive business days. The company has until November 12, 2025, to regain compliance, or it may face delisting.